Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,356 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07049055RecruitingPhase 1/Phase 2
EDV nanocell therapy with chemo for advanced pancreatic cancer
This trial tests a new targeted therapy (EDV nanocells) combined with two standard chemotherapy drugs for people with metastatic pancreatic cancer. It is for patients whose cancer has progressed after first-line FOLFIRINOX or NALIRIFOX treatment.
El Segundo, CaliforniaAges 18 years+ - NCT07050043RecruitingPhase 3
Low-dose nivolumab plus chemo vs standard chemo for advanced lung cancer
This trial tests whether a lower dose of the immunotherapy drug nivolumab combined with standard chemotherapy works better than chemotherapy alone for people with advanced or metastatic non-small cell lung cancer (NSCLC) that has not been treated before.
Alor Star, KedahAges 18 years+ - NCT07053033RecruitingPhase 2
Laser surgery or surgery plus second radiation for recurrent brain tumors
This trial is testing whether a second, precise dose of radiation to the brain, after a tumor has been removed or treated with a laser, can help people with recurrent brain metastases. It's for patients whose brain tumors have come back after prior radiation therapy.
Houston, TexasAges 18 years+ - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT07057102Recruiting
Gene testing to predict lung cancer treatment response and monitor recurrence
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07057596RecruitingPhase 2
Tebentafusp before surgery for uveal melanoma in the liver
This trial tests a drug called tebentafusp before surgery for uveal melanoma that has spread to the liver. The goal is to see if giving the drug first can shrink the tumors and make surgery more effective.
Berlin, State of BerlinAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT07066982RecruitingPhase 1/Phase 2
CAR T cells targeting CD146 and HER2 for advanced sarcomas
This trial tests a new type of immunotherapy where your own immune cells are modified to find and attack sarcoma cells that carry markers called CD146 or HER2. It is for people with advanced sarcoma who have already tried standard treatments.
Beijing, Beijing MunicipalityAges 21–90 - NCT07068529Recruiting
Metabolic biomarkers for early diagnosis and recurrence of colorectal cancer
This study looks at metabolic biomarkers in blood and tumor tissue to help detect colorectal cancer earlier, predict outcomes, and monitor for recurrence. It includes both people newly diagnosed with colorectal cancer and healthy volunteers for comparison.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07076823RecruitingPhase 1
Canagliflozin for MSI-H colorectal cancer
This trial tests a diabetes drug, canagliflozin, for people with a specific type of colorectal cancer (MSI-H). It's for those whose cancer has continued to grow after at least two standard treatments.
Chengdu, SichuanAges 18–80 - NCT07076979Recruiting
Metabolic biomarkers for stomach cancer detection and monitoring
This study looks for metabolic markers in your blood and tumor tissue to help find stomach cancer early, predict your prognosis, and watch for recurrence. If you qualify, you would give blood and tumor samples for testing.
ShanghaiAges 18 years+ - NCT07084571Recruiting
Testing Tissue Sampling Over Time in Advanced Breast Cancer
This study is testing whether it is safe and practical to take multiple small tissue samples (biopsies) from different sites of your breast cancer over time. The goal is to learn how breast cancer changes as it grows, which could help doctors develop better treatments.
LondonAges 18 years+ - NCT07085650Recruiting
Atrial Fibrillation Ablation Study
This study is for people with atrial fibrillation who are planning to have a catheter ablation procedure. It will look at how well the heart works after the procedure and how to prevent future events.
Shenyang, LiaoningAges 18 years+ - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07098598RecruitingPhase 2/Phase 3
Using FAPI-PET to diagnose pancreatic cancer
This trial uses a special imaging scan called FAPI-PET to help doctors better diagnose pancreatic cancer. If you are suspected of having pancreatic cancer or a recurrence, this study may help confirm or clarify your diagnosis.
TurkuAges 18–85 - NCT07104058Recruiting
FAPI PET scan to predict relapse in IgG4-RD
This study tests whether a special PET scan (FAPI PET/CT) can detect tiny signs of disease activity (MRD) in people with stable IgG4-RD, and whether it helps predict who might relapse.
Beijing, Beijing MunicipalityAges 18–75 - NCT07108270RecruitingPhase 2
Study of dostarlimab plus chemotherapy for advanced or recurrent endometrial cancer
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
Jinan, ShandongAges 18 years+ - NCT07115277Recruiting
A new imaging test for prostate cancer that has come back
This study tests a new imaging drug called Flotufolastat F-18 to find prostate cancer that has returned after treatment. The goal is to see how well and safely it finds the cancer spots, which could help guide next steps.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07117227Recruiting
Study to test a kidney cancer prediction model
This study is checking how well a model can predict the outcomes for people with kidney cancer who have had surgery. It looks at your medical records after surgery to help doctors better understand your recovery and future risks.
Beijing, Beijing MunicipalityAges 18–80 - NCT07120334Recruiting
Mobile health app for stroke survivors with prediabetes or diabetes
This trial tests a mobile app that helps people recovering from a stroke who also have prediabetes or type 2 diabetes improve their diet and health. You will use the app for about 12 weeks, and it may help you manage your blood sugar and prevent future strokes.
Honolulu, HawaiiAges 30–65 - NCT07121998Recruiting
Study of resistance to alkylating chemotherapy in endocrine tumors
This study looks at why some endocrine tumors (tumors in hormone-making glands) stop responding to a specific type of chemotherapy called alkylating agents. Researchers will collect tissue samples to understand how the tumor changes and why the medicine stops working.
UppsalaAges 18 years+ - NCT07122947Recruiting
Apple Watch to detect AFib after heart surgery
This study tests if an Apple Watch can help detect when atrial fibrillation (an irregular heartbeat) comes back after heart surgery. You'll wear an Apple Watch and a small skin patch (Zio Patch) to track your heart rhythm.
St Louis, MissouriAges 22 years+ - NCT07125183RecruitingPhase 2
Weekly chemo for advanced leiomyosarcoma in older adults
This trial tests whether weekly doxorubicin is effective and tolerable for people aged 65 and older with advanced or metastatic leiomyosarcoma. It may be a good option if you have not had this type of chemo before.
Aurora, ColoradoAges 65–100
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,356 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.